- Home
- EDU vs QGEN Comparison
EDU vs QGEN Comparison
Compare EDU & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDU | QGEN |
|---|---|---|
| Founded | 1993 | 1986 |
| Country | China | Netherlands |
| Employees | 84111 | 5500 |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 8.5B |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | EDU | QGEN |
|---|---|---|
| Price | $58.81 | $41.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $62.80 | $45.76 |
| AVG Volume (30 Days) | 819.3K | ★ 2.7M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | 2.25% | ★ 7.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.83 | $8.18 |
| Revenue Next Year | $11.16 | $5.71 |
| P/E Ratio | $24.75 | ★ $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.25 | $32.53 |
| 52 Week High | $64.97 | $57.82 |
Technical Indicators
Market Signals| Indicator | EDU | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 76.03 | 56.97 |
| Support Level | $58.45 | $39.08 |
| Resistance Level | $61.28 | $42.33 |
| Average True Range (ATR) | 1.92 | 0.82 |
| MACD | 1.03 | -0.10 |
| Stochastic Oscillator | 85.89 | 63.73 |
Price Performance
Historical ComparisonAbout EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).